Katherine Hsin-Yu Chau1, Rebecca Scherzer, Carl Grunfeld, Priscilla Ying Hsue, Michael G Shlipak. 1. *Department of Medicine, University of California, San Francisco, San Francisco, California;†Kidney Health Research Collaborative, San Francisco VA Medical Center, University of California, San Francisco, San Francisco, California; and‡Cardiology Division, San Francisco General Hospital, University of California, San Francisco, San Francisco, California.
Abstract
BACKGROUND: The prevalence of atrial fibrillation in the HIV-infected population is growing, but the ability of the CHA2DS2-VASc score to predict thromboembolic (TE) risk is unknown in this population. SETTING: Within the Veterans Affairs HIV Clinical Case Registry, 914 patients had an atrial fibrillation diagnosis between 1997 and 2011 and no previous TE events. METHODS: We compared TE incidence by CHA2DS2-VASc scores and stratified by warfarin use. Using Cox proportional hazards regression with adjustment for competing risks, we modeled associations of CHA2DS2-VASc scores and warfarin use with TE risk. RESULTS: At baseline, the distribution of CHA2DS2-VASc scores was 0 (n = 208), 1 (n = 285), and 2+ (n = 421); 34 patients developed 38 TE events during a median of 3.8 years follow-up. Event rates by CHA2DS2-VASc scores of 0, 1, and 2+ were 5.4, 9.3, and 8.1 per 1000 person years, respectively; multivariate-adjusted hazards ratios (HRs) were 1.70 (95% confidence interval: 0.65 to 4.45) for CHA2DS2-VASc score 1 (P = 0.28) and HR = 1.34 (0.51, 3.48) for score 2+ versus 0 (P = 0.55). Baseline warfarin use was associated with increased TE risk, although not statistically significant [HR 2.06 (0.86, 4.93), P = 0.11] with similar results when modeled as time-updated use and duration of use. CONCLUSION: In this national registry of HIV-infected veterans with atrial fibrillation, CHA2DS2-VASc scores were only weakly associated with TE risk. Furthermore, warfarin did not seem to be effective at preventing TE events. These results should raise concerns about the optimal strategy for TE prevention among HIV-infected persons with atrial fibrillation.
BACKGROUND: The prevalence of atrial fibrillation in the HIV-infected population is growing, but the ability of the CHA2DS2-VASc score to predict thromboembolic (TE) risk is unknown in this population. SETTING: Within the Veterans Affairs HIV Clinical Case Registry, 914 patients had an atrial fibrillation diagnosis between 1997 and 2011 and no previous TE events. METHODS: We compared TE incidence by CHA2DS2-VASc scores and stratified by warfarin use. Using Cox proportional hazards regression with adjustment for competing risks, we modeled associations of CHA2DS2-VASc scores and warfarin use with TE risk. RESULTS: At baseline, the distribution of CHA2DS2-VASc scores was 0 (n = 208), 1 (n = 285), and 2+ (n = 421); 34 patients developed 38 TE events during a median of 3.8 years follow-up. Event rates by CHA2DS2-VASc scores of 0, 1, and 2+ were 5.4, 9.3, and 8.1 per 1000 person years, respectively; multivariate-adjusted hazards ratios (HRs) were 1.70 (95% confidence interval: 0.65 to 4.45) for CHA2DS2-VASc score 1 (P = 0.28) and HR = 1.34 (0.51, 3.48) for score 2+ versus 0 (P = 0.55). Baseline warfarin use was associated with increased TE risk, although not statistically significant [HR 2.06 (0.86, 4.93), P = 0.11] with similar results when modeled as time-updated use and duration of use. CONCLUSION: In this national registry of HIV-infected veterans with atrial fibrillation, CHA2DS2-VASc scores were only weakly associated with TE risk. Furthermore, warfarin did not seem to be effective at preventing TE events. These results should raise concerns about the optimal strategy for TE prevention among HIV-infectedpersons with atrial fibrillation.
Authors: J Fellay; K Boubaker; B Ledergerber; E Bernasconi; H Furrer; M Battegay; B Hirschel; P Vernazza; P Francioli; G Greub; M Flepp; A Telenti Journal: Lancet Date: 2001-10-20 Impact factor: 79.321
Authors: M G Law; N Friis-Møller; W M El-Sadr; R Weber; P Reiss; A D'Arminio Monforte; R Thiébaut; L Morfeldt; S De Wit; C Pradier; G Calvo; O Kirk; C A Sabin; A N Phillips; J D Lundgren Journal: HIV Med Date: 2006-05 Impact factor: 3.180
Authors: Carl Grunfeld; Donald P Kotler; Donna K Arnett; Julian M Falutz; Steven M Haffner; Paul Hruz; Henry Masur; James B Meigs; Kathleen Mulligan; Peter Reiss; Katherine Samaras Journal: Circulation Date: 2008-06-19 Impact factor: 29.690
Authors: Markella V Zanni; Kathleen V Fitch; Meghan Feldpausch; Allison Han; Hang Lee; Michael T Lu; Suhny Abbara; Heather Ribaudo; Pamela S Douglas; Udo Hoffmann; Janet Lo; Steven K Grinspoon Journal: AIDS Date: 2014-09-10 Impact factor: 4.177
Authors: Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy Journal: J Am Coll Cardiol Date: 2014-03-28 Impact factor: 24.094
Authors: Albert M Anderson; Tanea Chane; Manish Patel; Shuo Chen; Wenqiong Xue; Kirk A Easley Journal: AIDS Patient Care STDS Date: 2012-06-28 Impact factor: 5.078
Authors: Stuart J Connolly; Janice Pogue; John Eikelboom; Gregory Flaker; Patrick Commerford; Maria Grazia Franzosi; Jeffrey S Healey; Salim Yusuf Journal: Circulation Date: 2008-10-27 Impact factor: 29.690
Authors: Andy I Choi; Yongmei Li; Steven G Deeks; Carl Grunfeld; Paul A Volberding; Michael G Shlipak Journal: Circulation Date: 2010-01-25 Impact factor: 29.690
Authors: Laura A Benjamin; Alan Bryer; Hedley C A Emsley; Saye Khoo; Tom Solomon; Myles D Connor Journal: Lancet Neurol Date: 2012-10 Impact factor: 44.182
Authors: Max Weyler Nery; Celina Maria Turchi Martelli; Erika Aparecida Silveira; Clarissa Alencar de Sousa; Marianne de Oliveira Falco; Aline de Cássia Oliveira de Castro; Jorge Tannus Esper; Luis Carlos Silva e Souza; Marília Dalva Turchi Journal: ScientificWorldJournal Date: 2013-10-21